Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease.

Iwama, Itaru; Yoshida, Masashi; Miyazawa, Ayako; Hara, Tomoko; Nambu, Ryusuke

Iwama, Itaru; Yoshida, Masashi; Miyazawa, Ayako; Hara, Tomoko; Nambu, Ryusuke.

Afiliação

Iwama I; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
Yoshida M; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
Miyazawa A; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
Hara T; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
Nambu R; Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.

Inflamm Bowel Dis ; 30(7): 1220-1222, 2024 Jul 03.

Article em En | MEDLINE | ID: mdl-38588461

We observed efficacy and safety of ustekinumab in very early-onset inflammatory bowel disease, which has not been previously reported. Clinical remission at 52% was 75%, often persisting beyond 2 years. Further studies including larger numbers of cases are needed to confirm this observation.

Assuntos

Doenças Inflamatórias Intestinais; Indução de Remissão; Ustekinumab; Humanos; Ustekinumab/uso terapêutico; Doenças Inflamatórias Intestinais/tratamento farmacológico; Feminino; Masculino; Idade de Início; Resultado do Tratamento

Palavras-chave

steroid-free clinical remission; ustekinumab; very early-onset inflammatory bowel disease

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Indução de Remissão / Doenças Inflamatórias Intestinais / Ustekinumab Limite: Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google